Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039723 · ClinicalTrials.gov registry record · Phase 4
Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
A Phase 4 study of Photoaging, sponsored by Main Line Center for Laser Surgery.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05039723: Completed Phase 4 study of Photoaging, sponsored by Main Line Center for Laser Surgery.
NCT05039723 is a Phase 4 study of Photoaging that has completed, run by Main Line Center for Laser Surgery. The registered enrollment target is 22 participants, below the 30-participant average among 14 other Photoaging trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05039723, a Phase 4 study of Photoaging, has completed, sponsored by Main Line Center for Laser Surgery.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label FDA-cleared indications.
Conditions Studied
Interventions
- DRUG Radiesse, Xeomin, Belotero
Study Locations (1)
Pennsylvania
- Main Line Center for Laser Surgery - Ardmore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 4 |
What the finished NCT05039723 record still lists
NCT05039723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 30-participant average among 14 other Photoaging trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Photoaging appearing as the primary indexed condition, and to 1 intervention - of which Radiesse, Xeomin, Belotero is the first listed.
NCT05039723 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05039723 about?
NCT05039723 is a clinical study titled "Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational". The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label...
What is the current status of trial NCT05039723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2021-09-01. Estimated completion is 2022-07-01.
What conditions does trial NCT05039723 study?
This clinical trial studies the following conditions: Photoaging.
What interventions are being tested in trial NCT05039723?
The interventions under investigation include: Radiesse, Xeomin, Belotero (DRUG).
Who is sponsoring clinical trial NCT05039723?
This trial is sponsored by Main Line Center for Laser Surgery, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039723 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Photoaging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05039723's enrollment target sits among peer trials
22 11th of 14 higher than 4 of 14 other Photoaging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Photoaging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles
COMPLETED · Phase 4
-
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
RECRUITING · NA
-
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
ACTIVE NOT RECRUITING · NA
-
Effect of Platelet Rich Plasma on Photoaged Skin
ACTIVE NOT RECRUITING · Phase 1
-
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation
COMPLETED · NA
-
Comparison of the Cosmetic Effects of Bakuchiol and Retinol
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI